Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 7Lymphoma, T-Cell 3Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Rituximab 2Epoetin Alfa 2Early Intervention, Educational 2Dexamethasone 2Darbepoetin alfa 2Bortezomib 2ponatinib 1pegaspargase 1isatuximab 1ibrutinib 1ibritumomab tiuxetan 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1cirmtuzumab 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Vincristine 1Sucrose 1Prednisone 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Etoposide 1Doxorubicin 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoproliferative Disorders × 10-propargyl-10-deazaaminopterin × Clear all
NCT01420679 2021-11-19

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
21 enrolled 8 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡